Lutetium-177 PSMA radionuclide treatment (Lu-PSMA) is another treatment for cutting edge prostate malignant growth. Lu-PSMA is a radioactive particle that explicitly joins to cells with high measures of PSMA on the outside of the cells. This enables the radioactivity to be conveyed essentially to the prostate malignancy cells wherever they have spread, while saving most typical tissues. Past little investigations of Lu-PSMA indicated promising movement in patients with cutting edge prostate malignancy.
This randomized investigation will contrast Lu-PSMA and a sort of chemotherapy called cabazitaxel, which is the standard treatment for cutting edge prostate disease when different medications have quit working. A large portion of the members will get Lu-PSMA and half will get cabazitaxel. This examination will give additional data about the dangers and advantages of Lu-PSMA contrasted and cabazitaxel in men with prostate malignant growth. We intend to enlist 200 members in the examination in Australia.
TheraP is an association between ANZUP Cancer Trials Group and the Prostate Cancer Foundation of Australia (PCFA) with help from the Australian Nuclear Science and Technology Organization (ANSTO), Endocyte, It’s a Bloke Thing, Movember and CAN4CANCER.